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2ABSTRACT26
Bexarotene is currently marketed for treatment of cutaneous T-cell lymphoma and there has27
been growing interest in its therapeutic effectiveness for other cancers. Neuroprotective effects28
of bexarotene have also been reported. In this study, a simple, sensitive and cost-efficient29
bioanalytical method for determination of bexarotene in rat plasma was developed and fully30
validated. The method utilises protein precipitation with acetonitrile and liquid-liquid31
extraction with n-hexane-ethyl acetate (10:1, v/v). An HPLC-UV system with a Waters Atlantis32
C18 column and a mobile phase of acetonitrile-ammonium acetate buffer (10 mM, pH 4.1) at33
a ratio of 75:25 (v/v), flow rate 0.2 mL/min was used. Chromatograms were observed by a UV34
detector with wavelength set to 259 nm. Intra- and inter-day validations were performed and35
sample stability tests were conducted at various conditions. The applicability of the method36
was demonstrated by a pharmacokinetic study in rats. Intravenous bolus dose of 2.5 mg/kg was37
administered to rats and samples were obtained at predetermined time points. As a result,38
pharmacokinetic parameters of AUCinf (4668 ± 452 h·ng/mL), C0 (6219 ± 1068 ng/mL) and39
t1/2 (1.15 ± 0.02 h) were obtained. In addition, the developed method was further applied to40
human and mouse plasma to assess the suitability of the method for samples from other species.41
42
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31. Introduction47
Bexarotene is an orally bioavailable synthetic rexinoid that selectively binds to retinoid X48
receptors [1]. It was the first selective retinoid that entered clinical trials [2] and it is currently49
approved for treatment of cutaneous T-cell lymphoma (CTCL) in patients whose disease is50
refractory to at least one systemic chemotherapy [3]. Following the approval, the efficacy and51
safety of bexarotene was shown in refractory early-stage CTCL [4] and other related conditions52
such as panniculitis-like T-cell lymphoma [5]. Bexarotene also showed certain promise in non-53
small cell lung cancer [6-9]. In addition, clinical trials are currently ongoing for efficacy in54
acute myeloid leukaemia [10, 11] and other tumours such as aerodigestive tract cancer [12],55
breast cancer [13], metastases of differentiated thyroid carcinoma [14] and keratoacanthomas56
[15].57
58
In the past few years, additional attention was drawn to bexarotene as it was reported to have59
neuroprotective effects [16, 17]. Preclinical studies have shown that bexarotene reverses60
cognitive and neuronal impairments and improves neural circuit function with a mechanism61
related to apolipoprotein E, therefore providing a new strategy for treatment of Alzheimer’s62
disease [18, 19]. These results were followed by additional studies which showed63
neuroprotective effects of bexarotene in Parkinson’s disease [20]. Although some debate on its64
effectiveness in neurodegenerative diseases still remains [21, 22], a clinical trial of bexarotene65
in Alzheimer’s disease is ongoing and a clinical trial in healthy volunteers to elucidate its66
neuroprotective mechanism is also being conducted [17]. Other clinical trials investigating67
potential indications of bexarotene include trials in chronic severe hand dermatitis [23],68
lymphomatoid papulosis [24], psoriasis [25], alopecia areata [26], schizophrenia [27] and69
Cushing’s disease [28].70
71
4In response to the extensive clinical research of bexarotene, interest in mechanistic preclinical72
studies to explore its benefits in cancer and other diseases persists. Apart from the already73
known anticancer effects such as inhibition of cell cycle progressions and induction of74
apoptosis [29], studies have demonstrated that bexarotene induces differentiation of cells,75
which can lead to treatment of cancer [30, 31]. It also prevents multidrug resistance, which is76
a major problem in chemotherapies [32] and other studies have shown that it has anticancer77
effects by inhibition of angiogenesis and metastasis [33]. Preventive effects of bexarotene have78
also been elucidated in lung cancer [34, 35], breast cancer [36] and intestinal cancer [37]. Other79
preclinical studies include research in neurodegenerative diseases as previously mentioned [38,80
39], and also research in cholesterol homeostasis [40, 41] and pharmacokinetic studies to81
interpret relationships between exposure and effects [6]. Additionally, recent pharmaceutical82
research of nano-crystalisation of bexarotene has been reported with bioanalysis of plasma83
samples for pharmacokinetics [42, 43]. Unfortunately, these studies have not included a84
validation of the analytical methods used.85
86
Previously published analytical methods for quantification of bexarotene in biological matrices87
include an assay that involves high-performance liquid chromatography (HPLC) with88
fluorescence detection [44]. This method achieved good sensitivity with lower limit of89
quantification (LLOQ) of 0.5 ng/mL and has been applied to clinical pharmacokinetic studies.90
However, it is limited by the fact that it requires a high volume of plasma (1 mL) to achieve91
this sensitivity. This could be a major limitation for preclinical studies in rodents as sample92
volume is usually substantially lower in these studies. Furthermore, the calibration curve of93
this method was separated into a low-range and a high-range, and the two ranges utilised94
different instruments for analysis. Additionally, there was no full validation of that analytical95
method to meet the guidelines proposed by the US Food and Drug Administration (FDA) [45].96
5Another published method employed gas chromatography-mass spectrometry to achieve97
LLOQ of 1 ng/mL, but requires a chemical derivatisation step which makes the method time-98
consuming, complicated and expensive [46]. A more simple analytical method using HPLC-99
UV has been reported but this study was focused on the metabolic pathway of bexarotene [47].100
Therefore it did not report specific details on the analytical procedure such as LLOQ,101
quantification range, use of an internal standard and validation.102
103
Therefore, the aim of this study was to develop a simple, sensitive and cost-efficient104
bioanalytical method for determination of bexarotene in rat plasma, utilising low-volume105
samples and a high-range calibration curve. The assay was developed using HPLC coupled106
with ultra-violet (UV) detection and full validation of the method was performed to meet the107
regulations of the FDA. The developed and validated method was applied to a pharmacokinetic108
study of intravenous bolus administration in rats. The suitability of the method for mouse and109
human plasma was also assessed in this study.110
111
2. Materials and methods112
2.1. Chemicals and reagents113
Bexarotene (CAS: 153559-49-0) was purchased from LC Laboratories (Woburn, MA, USA).114
For internal standard (IS), ∆9-tetrahydrocannabinol (CAS: 1972-08-3) was used (from THC115
Pharm GmbH (Frankfurt, Germany)). Rat and mouse plasma were purchased from Sera116
Laboratories (West Sussex, UK) and human plasma from TCS Biosciences (Buckingham, UK).117
All solvents were of HPLC grade and were purchased from Fisher Scientific (Leicestershire,118
UK). All other reagents were purchased from commercial sources and were of HPLC grade or119
higher.120
121
62.2. Instrumentation122
2.2.1. Analytical equipment123
The HPLC-UV system consisted of a Waters Alliance 2695 separations module coupled with124
a Waters 996 photodiode array detector. The samples in the autosampler were maintained at125
4°C and a column oven was used to control the column temperature at 40°C. EmpowerTM 2126
software was used for data processing.127
128
2.2.2. Analytical conditions129
Chromatographic separation was achieved by Waters Atlantis C18 2.1 × 150 mm, 5 µm particle130
size column (Milford, MA, USA) equipped with a SecurityGuard 2 × 4 mm, 3 µm particle size131
(Phenomenex, Macclesfield, UK). A mobile phase mixture of acetonitrile/ammonium acetate132
buffer (10 mM, pH modified to 4.1 with glacial acetic acid) was used in a ratio of 75:25 (v/v).133
The mobile phase was eluted with isocratic conditions at 0.2 mL/min. The analytes were134
detected at 259 nm.135
136
2.3. Sample preparation137
2.3.1. Preparation of calibration curve standards and quality control samples138
Stock standard solutions of bexarotene and IS were prepared at concentration of 1 mg/mL in139
acetonitrile and were stored at -20°C. Working standard solutions of bexarotene were prepared140
by diluting the stock standard solution with acetonitrile to yield concentrations of 0.1, 0.2, 0.5,141
1, 5, 10, 50 and 100 µg/mL. Working standard solution of the IS was prepared in the same142
manner to yield a concentration of 100 µg/mL. Plasma calibration curve samples were prepared143
by spiking 100 µL of plasma with 10 µL of corresponding working standard solutions of144
bexarotene to yield concentrations of 10, 20, 50, 100, 500, 1000, 5000 and 10000 ng/mL.145
146
7Working standard solutions of bexarotene for quality control samples were prepared in a147
similar procedure at concentrations of 0.1, 0.25, 4 and 80 µg/mL. Ten µL of working standard148
solutions were spiked to 100 µL of plasma to give lower limit of quantification (LLOQ), low149
quality control (LQC), medium quality control (MQC) and high quality control (HQC) samples150
at concentrations of 10, 25, 400 and 8000 ng/mL, respectively. These calibration curve and151
quality control samples then underwent sample preparation procedure as described below.152
153
2.3.2. Sample preparation procedure154
For the sample preparation, 10 µL of IS solution (100 µg/mL) was added to 100 µL of plasma155
sample. Protein precipitation of the samples was performed by adding 300 µL of acetonitrile.156
For pH modification, 300 µL of 0.1 M HCl was then added. The samples were briefly vortex-157
mixed for 1 min and extraction solvent (3.3 mL) consisting of n-hexane-ethyl acetate (10:1,158
v/v) was added. The samples were vortex-mixed for 10 min and were centrifuged at 1160 g for159
10 min at 10°C (Harrier 18/80R, UK). The upper organic layer was transferred and evaporated160
to dryness under gentle stream of N2 gas at 40°C (Techne DRI-Block type DB-3D, Cambridge,161
UK). Reconstitution solvent (100 µL) of acetonitrile-water (1:1, v/v) was added to the residue162
and the samples were vortex-mixed for 10 min. A volume of 40 µL was injected into the HPLC-163
UV system for analysis.164
165
2.4. Bioanalytical method validation166
Full validation of the bioanalytical method was conducted in accordance with the guideline167
established by the FDA [45].168
169
2.4.1. Selectivity170
8The selectivity of the developed bioanalytical method was assessed by comparing the171
chromatograms of plasma samples spiked with bexarotene (n = 6) at the LLOQ with the172
chromatograms of blank plasma samples. It was also assessed in plasma samples obtained from173
the pharmacokinetic experiment in rats [45].174
175
176
2.4.2. Accuracy and precision177
Accuracy was the bias from nominal concentration and was expressed as relative error (RE).178
Precision was the coefficient of variation and was expressed as relative standard deviation179
(RSD). The intra-day accuracy and precision were validated by preparing and analysing six180
replicates of QC samples (LLOQ, LQC, MQC and HQC) on the same day. The inter-day181
accuracy and precision were validated by preparing and analysing six replicates of QC samples182
on six different days. The acceptable values for accuracy and precision were RE within ±15%183
and RSD ≤15%, respectively, with the exception of RE within ±20% and RSD ≤20%, 184
respectively, for the LLOQ.185
186
2.4.3. Sensitivity187
The LLOQ was determined as the lowest tested concentration of bexarotene in spiked plasma188
that had acceptable accuracy and precision of RE within ±20% and RSD ≤20%, respectively, 189
from intra-day and inter-day analyses [45].190
191
2.4.4. Linearity192
Calibration curves were constructed at the range of 10 – 10000 ng/mL as described above with193
10 ng/mL as LLOQ. A double blank sample (unspiked plasma) and a blank sample (plasma194
spiked with IS solution only) were included in each calibration curve. The peak ratio between195
9bexarotene and the IS was plotted against nominal concentration to obtain calibration curves.196
Calibration curves with correlation coefficient (r2) values of >0.99 and accuracy of ±15%197
(except for LLOQ where ±20% was applied) were considered to be acceptable.198
199
2.4.5. Recovery200
The recovery of bexarotene was determined by comparing the peak areas of processed samples201
with peak areas of solutions of equivalent concentration in the reconstitution solvent mixture202
[45]. It was expressed as the mean ± SD from three concentrations tested (LQC, MQC and203
HQC). The recovery of IS was determined in the same manner at a concentration of 10 µg/mL.204
205
2.4.6. Freeze and thaw stability206
Three freeze-thaw cycles (freezing at -80°C for 24 h and thawing at room temperature) were207
applied to six replicates of QC samples (LQC, MQC and HQC). Following the third freeze-208
thaw cycle the samples were processed and a freshly prepared set of calibration curve was used209
for quantification.210
211
2.4.7. Bench-top, short-term and long-term stability212
Sample stability studies were performed with six replicates of QC samples (LQC, MQC and213
HQC). Bench-top stability was assessed by preparing the QC samples and storing them at room214
temperature for 6 h. The QC samples for short-term stability were prepared and stored at -20°C215
for 24 h. Long-term stability was tested by storing the QC samples for 2, 4 and 8 weeks at -216
80°C. After desired storage time, the samples underwent sample preparation procedure as217
described in section 2.3.2. Quantification was performed using a calibration curve freshly218
prepared each time.219
220
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2.4.8. Autosampler stability221
Six replicates of QC samples (LQC, MQC and HQC) were prepared and processed according222
to the sample preparation procedure described above. These processed samples were stored at223
4°C for 24 h to mimic the condition inside the autosampler of HPLC-UV system. After 24 h,224
the analysis was performed and the samples were quantified using a freshly prepared225
calibration curve.226
227
2.4.9. Stock solution stability228
Working standard solutions for QC samples were prepared at concentrations of 0.25, 4 and 80229
µg/mL and were stored in room temperature for 6 h. These solutions were then used to prepare230
six replicates of QC samples (LQC, MQC and HQC) and they were submitted for sample231
preparation procedure. Calibration curve samples used for quantification of these QC samples232
were prepared at the time of sample preparation procedure.233
234
2.5. Pharmacokinetic study235
2.5.1. Animals236
All procedures of the in vivo pharmacokinetic study were reviewed and approved by the237
University of Nottingham Ethical Review Committee in accordance with the Animals238
[Scientific Procedures] Act 1986. Male Sprague Dawley rats (Charles River Laboratories, UK)239
weighing 350-380 g were used for the experiment. They were housed in the Bio Support Unit,240
University of Nottingham, with controlled temperature, 12 h light/dark cycle and free access241
to food and water. The acclimatisation of the animals was at least for six days. On the day of242
surgery, general anaesthesia was induced by intraperitoneal administration of a mixture of243
ketamine (90 mg/kg) and xylazine (8 mg/kg) and right jugular vein cannulation was performed.244
The rats were then allowed to recover for two nights before the experimental procedures.245
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2.5.2. Experimental procedure246
A dosing formulation of bexarotene was prepared at 2.5 mg/mL in polyethylene glycol 400.247
Intravenous bolus dose of 2.5 mg/kg was administered to the rats and blood samples (0.25 mL)248
were collected before administration, and at 5, 15, 30, 45, 60, 120, 240 and 480 min after the249
administration via the jugular vein cannula. Plasma samples were obtained by centrifugation250
(3000 g, 10 min) and were stored at -80°C until analysis. Non-compartmental pharmacokinetic251
analysis of the plasma concentration profiles were performed using Phoenix WinNonlin 6.3252
software (Pharsight, Mountain View, CA, USA).253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
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3. Results and discussion271
3.1. Method development272
As bexarotene is a weak acid (pKa = 4.08, predicted by ACD/Labs, Toronto, Canada), to273
improve the extraction efficiency, the pH of plasma samples was modified using 0.1 M HCl274
following protein precipitation with acetonitrile. When 0.1 M HCl was not added to plasma,275
major fraction of bexarotene stayed in the ionised form, resulting in poor recovery. After276
acidification of the samples, bexarotene was easily extracted. Since bexarotene is a highly277
lipophilic compound (Log P = 8.55, predicted by ACD/Labs, Toronto, Canada), non-polar278
organic solvents were considered to be suitable for the extraction step [48-50]. Extraction using279
n-hexane was attempted initially, but interestingly addition of ethyl acetate, a relatively polar280
extraction solvent, improved recovery of bexarotene. However, increasing the ratio of ethyl281
acetate further decreased the recovery and finally n-hexane-ethyl acetate with the ratio of 10:1282
(v/v) was selected as the extraction solvent.283
284
For the mobile phase mixture, water was initially tried as the aqueous component. However,285
bexarotene was not efficiently retained in the C18 column as it had an ionised form in water.286
Therefore 10 mM ammonium acetate buffer was used instead of water. The pH of the buffer287
was tested at a range of 4.0-5.5 and from the shift of retention time, it was found that bexarotene288
was better retained at lower pH. The final pH of the buffer (pH 4.1) and the composition ratio289
with acetonitrile were selected to provide optimal selectivity and sensitivity.290
291
3.2. Method validation292
3.2.1. Selectivity293
The selectivity of the method was demonstrated as interference peaks from blank rat plasma294
samples were effectively separated from the peak of bexarotene (Figure 1). It is also shown in295
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Figure 1D that endogenous peaks that originate from plasma of rats used in pharmacokinetic296
experiments did not interfere with the peaks of interest. Therefore the current method provides297
selective determination of bexarotene in rat plasma. The inability of UV-based analytical298
methods to detect metabolites can be a limitation of this method.299
300
3.2.2. Accuracy and precision301
Accuracy and precision, expressed as RE and RSD, respectively, for intra- and inter-day302
validations are shown in Table 1. The values for all QC samples (LQC, MQC and HQC) were303
within the acceptable range (RE within ±15% and RSD <15%). The values for LLOQ samples304
were also within the criteria (RE within ±20% and RSD <20%), indicating that the developed305
method was able to quantify bexarotene with appropriate accuracy and precision [45].306
307
308
309
310
311
3.2.3. Sensitivity and linearity312
As mentioned in the previous section, the LLOQ samples had acceptable accuracy and313
precision in intra- and inter-day validations and therefore 10 ng/mL was determined to be the314
LLOQ for the developed method (Table 1). The linearity of the calibration curves was315
established over a range of 10-10000 ng/mL as all the points within the calibration curve,316
except LLOQ, were within the criteria of RE within ±15% and RSD <15% and the correlation317
coefficient (r2) values were >0.99. The LLOQ of 10 ng/ml is sufficiently sensitive to support318
preclinical pharmacokinetic studies in rats.319
320
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3.2.4. Recovery321
The absolute recoveries (mean ± SD) of bexarotene from rat plasma were 96.2 ± 0.6%, 97.2 ±322
1.1%, and 96.0 ± 2.8% for the LQC, MQC and HQC samples, respectively. Such high recovery323
was reached by optimising the extraction solvent. The high recovery of this method contributed324
to achieving good sensitivity. The recovery of the IS was 89.4 ± 2.7%.325
326
3.2.5. Stability327
The stability of spiked rat plasma samples under different storage conditions is shown in Table328
2. The RE and RSD values were within acceptable limits for all conditions tested. The bench-329
top stability and stock solution stability ensures that the samples and stock solutions are stable330
during sample preparation procedures, respectively. Short- and long-term stability results331
indicate that these samples can be stored under these conditions without compromising the332
accuracy and precision. Samples that had undergone freeze-thaw cycles have demonstrated that333
stability is not affected up to three cycles. Also, autosampler stability indicates that processed334
samples can be stored in the autosampler for up to 24 h. Although some stability data in human335
plasma samples with bexarotene has been previously reported, it only included bench-top,336
freeze-thaw cycles and autosampler stabilities [44]. To the best of our knowledge, the present337
study is the first report of full validation in rat plasma, including all the stability tests required338
by the FDA [45].339
340
3.3. Pharmacokinetic study in rats341
The applicability of the analytical method was demonstrated in a pharmacokinetic study in rats342
following IV bolus administration. The plasma concentration-time profiles of bexarotene are343
shown in Figure 2 and pharmacokinetic parameters obtained by non-compartmental analysis344
are shown in Table 3. The plasma concentration profiles showed consistency across the animals345
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(Figure 2) which is also reflected in the variability of the obtained pharmacokinetic parameters346
(Table 3). The selectivity, sensitivity and range of the calibration curve of the developed347
method are sufficient to be utilised in pharmacokinetic studies in rats.348
349
3.4. Assessment of the suitability of the analytical method to human and mouse plasma.350
Following the development and validation of the bioanalytical method for rat plasma, it was351
further applied to human and mouse plasma to assess the potential suitability of the352
methodology for studies in additional species. The same sample preparation method was353
applied to both human and mouse plasma for the levels of LQC, MQC and HQC. The validity354
was assessed by inter-day validation and the accuracy and precision are shown in Table 4.355
Good selectivity was also exhibited by comparing chromatograms of spiked samples and blank356
plasma samples for both human and mouse plasma (Figures 3 and 4, respectively). The only357
remarkable point was that for human plasma, an interference peak appeared at the retention358
time of IS (Figure 3). The problem was solved by observing the IS peak at 220 nm for human359
plasma only (Figure 3). These results show that the current method has good potential to be360
utilised in studies involving both human subjects and mice. A bioanalytical method for361
determination of bexarotene in mouse plasma has not been previously reported.362
363
4. Conclusion364
The present study describes development and full validation of a simple, sensitive and cost-365
efficient bioanalytical method using HPLC-UV for the determination of bexarotene in rat366
plasma. This method utilises 100 μL volume of samples to achieve LLOQ adequate to support 367
preclinical pharmacokinetic studies. A full validation of a bioanalytical method for bexarotene368
in rat plasma is reported here for the first time. It was also shown that the method can be applied369
to studies involving human subjects and mice.370
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FIGURE CAPTIONS541
542
Figure 1. Representative chromatograms from rat plasma. A, Rat plasma spiked with 10 µg/mL543
of IS; B, rat plasma spiked with 10 ng/mL bexarotene and 10 µg/mL of IS (LLOQ sample); C,544
rat plasma spiked with 100 ng/mL bexarotene and 10 µg/mL of IS (calibration curve sample);545
D, rat plasma sample obtained in pharmacokinetic study 1 h following intravenous bolus546
administration of 2.5 mg/kg bexarotene. All observed at λ = 259 nm. 547
548
Figure 2. Plasma concentration-time profiles of bexarotene following intravenous bolus549
administration at 2.5 mg/kg in rats (n = 3).550
551
Figure 3. Representative chromatograms from human plasma. A, blank human plasma552
observed at λ = 259 nm; B, human plasma spiked with 400 ng/mL bexarotene observed at λ = 553
259 nm (MQC sample); C, blank human plasma observed at λ = 220 nm; D, human plasma554
spiked with 10 µg/mL of IS observed at λ = 220 nm. 555
556
Figure 4. Representative chromatograms from mouse plasma. A, blank mouse plasma; B,557
mouse plasma spiked with 400 ng/mL bexarotene and 10 µg/mL of IS (MQC sample). All558
observed at λ = 259 nm. 559
560
561
Table 1. Intra- and inter-day validation results of the analytical method of bexarotene in rat plasma using HPLC-UV (n = 6)
Concentration
levels
Intra-day Inter-day
Accuracy (RE, %) Precision (RSD, %) Accuracy (RE, %) Precision (RSD, %)
LLOQ (10 ng/mL) 4.67 6.10 -2.73 14.30
LQC (25 ng/mL) -5.06 10.00 -0.27 7.57
MQC (400 ng/mL) 7.57 3.00 -0.82 12.27
HQC (8000 ng/mL) 7.93 3.50 0.54 9.63
LLOQ, lower limit of quantification; LQC, low quality control; MQC, medium quality control; HQC, high quality control.
Table 2. Stability results of rat plasma samples of bexarotene under various storage conditions (n = 6)
Concentration
levels
Benchtop
stability
(25°C, 6 h)
Short term
stability
(-20°C, 24 h)
Autosampler
stability
(4°C, 24 h)
Freeze-thaw
stability
(-80°C, 3
cycles)
Stock solution
stability
(25°C, 6 h)
Long term
stability
(-80°C, 2 wks)
Long term
stability
(-80°C, 4 wks)
Long term
stability
(-80°C, 8 wks)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
LQC
(25 ng/mL) 0.14 7.05 -3.99 3.78 7.88 4.27 -2.86 13.14 -4.14 4.08 -10.18 6.78 -8.21 4.07 -3.73 6.49
MQC
(400 ng/mL) 7.81 4.84 -2.41 10.46 12.20 2.69 -1.83 12.17 -2.48 1.68 -13.94 5.72 -7.91 5.52 -8.32 2.64
HQC
(8000 ng/mL) 7.58 6.07 -1.67 6.63 -5.83 5.75 -3.30 8.78 -8.53 11.56 -11.39 9.79 -1.65 6.54 -7.61 2.50
RE, relative error; RSD, relative standard deviation; LQC, low quality control; MQC, medium quality control; HQC, high quality control.
Table 3. Pharmacokinetic parameters of bexarotene obtained following intravenous bolus administration of 2.5 mg/kg bexarotene in rats (n = 3)
Parameters Mean SD
AUC0→t (h·ng/mL) 4631 453
AUCinf (h·ng/mL) 4668 452
C0 (ng/mL) 6219 1068
t1/2 (h) 1.15 0.02
Vss (mL/kg) 734 104
CL (mL/h/kg) 539 55
AUCinf, area under the curve from time zero to infinity; AUC0t, area under the curve from time
zero to the last sampling time point; C0, concentration extrapolated to time zero; t1/2, half-life;
Vss, volume of distribution at steady state; CL, clearance.
Table 4. Intra-day validation results of the analytical method of bexarotene in human and mouse plasma using HPLC-UV (n = 6)
Concentration
levels
Human plasma Mouse plasma
Accuracy (RE, %) Precision (RSD, %) Accuracy (RE, %) Precision (RSD, %)
LQC (25 ng/mL) -2.67 8.52 5.59 7.08
MQC (400 ng/mL) -1.69 13.04 10.75 5.87
HQC (8000 ng/mL) -5.49 14.65 6.96 3.54
RE, relative error; RSD, relative standard deviation; LQC, low quality control; MQC, medium quality control; HQC, high quality control.
